OZE: Influenza A And Influenza B Multiplex Nucleic Acid Assay
What it covers
An Influenza A and Influenza B multiplex nucleic acid assay is a multiplex in vitro diagnostic test for the simultaneous qualitative detection and discrimination of influenza A and influenza B nucleic acids isolated and purified from human respiratory specimens obtained from individuals exhibiting signs and symptoms of respiratory tract infections or viral culture. The detection and discrimination of influenza A and B nucleic acids from symptomatic patients aid in the diagnosis of human respiratory tract influenza viral infections if used in conjunction with other clinical and laboratory findings.
FDA’s definition of product code OZE, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K263035 | CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel (includes Influenza A/B Typing Kit, Influenza A Subtyping Kit, Influenza A(H5) Subtyping Kit, and Influenza B Lineage Genotyping Kit) | Centers for Disease Control and Prevention | Sep 30, 2026 | Special |
| K243274 | CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A SubTyping Kit (VER 4); Influenza B Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4) | Centers for Disease Control and Prevention | Jul 11, 2025 | Traditional |
| K243931 | CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A Subtyping Kit (VER 4); Influenza B Lineage Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4) | Centers for Disease Control and Prevention | Mar 14, 2025 | Traditional |
| K241110 | CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit (Ver4) | Centers for Disease Control and Prevention | May 21, 2024 | Special |
| K230236 | Lyra Influenza A+B Assay | Quidel Corporation | Mar 3, 2023 | Special |
| K220801 | ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2 | Abbott Diagnostics Scarborough, Inc. | Jun 24, 2022 | Special |
| K200370 | CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit, CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza A/H5 Subtyping Kit | Centers for Disease Control and Prevention | Mar 10, 2020 | Special |
| K182513 | FluChip-8G Influenza A+B Assay | Indevr, Inc. | Apr 22, 2019 | Traditional |
| K190302 | CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit, CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza B Lineage Genotyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza A/HS Subtyping Kit | Centers for Disease Control and Prevention | Mar 27, 2019 | Traditional |
| K190204 | ID NOW Influenza A & B 2 | Alere Scarborough, Inc. | Mar 18, 2019 | Special |
Clearances by year
21 OZE 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 1 | 30 |
| 2025 | 2 | 176 |
| 2024 | 1 | 29 |
| 2023 | 1 | 32 |
| 2022 | 1 | 98 |
| 2020 | 1 | 25 |
| 2019 | 3 | 43 |
| 2018 | 2 | 139 |
| 2017 | 1 | 29 |
| 2016 | 1 | 24 |
| 2015 | 1 | 32 |
| 2014 | 3 | 22 |
| 2013 | 2 | 60 |
| 2012 | 1 | 85 |
Who submits
9 applicants cleared a OZE device since 2011. 100% of the clearances went to applicants in United States. By type: Special 57%, Traditional 38% and Dual Track 5%.
| Applicant | Clearances since 2011 |
|---|---|
| Centers for Disease Control and Prevention | 10 |
| Centers For Disease Control and Prevention (CDC) | 3 |
| Quidel Corp. | 2 |
| Abbott Diagnostics Scarborough, Inc. | 1 |
| Alere Scarborough, Inc. | 1 |
| Center For Disease Control and Prevention (Cdc) | 1 |
| Indevr, Inc. | 1 |
| Mesa Biotech, Inc. | 1 |
How FDA classifies it
Class II (special controls). The special controls are:
(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;”
(2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and
(3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.
From 21 CFR 866.3980. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 866.3980 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent OZE clearances declared.
Ask about OZE
Questions about OZE
What is FDA product code OZE?
Product code OZE, “Influenza A And Influenza B Multiplex Nucleic Acid Assay” in FDA's classification database, is a Class II device type under 21 CFR 866.3980 (respiratory viral panel multiplex nucleic acid assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 21 clearances under OZE, 21 of them since 2011.
How many 510(k) clearances are there under OZE?
FDA’s 510(k) database listed 21 clearances under OZE as of Oct 29, 2026, 21 of them decided since 2011; the most recent decision was Sep 30, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a OZE 510(k)?
For the 3 OZE clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 84 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most OZE clearances?
Since 2011: Centers for Disease Control and Prevention (10), Centers For Disease Control and Prevention (CDC) (3), Quidel Corp. (2), Abbott Diagnostics Scarborough, Inc. (1) and Alere Scarborough, Inc. (1). 9 applicants have cleared a OZE device in that time.